Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Organ-on-a-Chip Conference

Kristin Fabre's Biography



Kristin Fabre, Microphysiological Systems Lead, Drug Safety & Metabolism, AstraZeneca

Dr. Fabre is part of Drug Safety and Metabolism, AstraZeneca as the Microphysiological Systems Development and Implementation Lead, working with several key AZ members to develop how to best utilize MPS technology for drug development and screening. Prior to joining AZ, she was the Scientific Program Manager for the Microphysiological Systems (or Organs-on-Chips) Initiative at NIH National Center for Advancing Translational Sciences (NCATS). This role included providing oversight on all MPS cooperative agreements, including members from FDA, DARPA, NIH and several academic institutions across the United States in addition to building public-private partnerships. Dr. Fabre received her BS in Biology from the University of Wyoming, followed by her MS and PhD from Colorado State University in Cell and Molecular Biology. Prior to joining NCATS, she completed her NIH National Cancer Institute postdoctoral fellowship, emphasizing research in cancer biology, DNA repair and radiation biology. During her time at the NCI, Dr. Fabre was highly involved with training programs and was Chair of the NCI Fellows and Young Investigators Steering Committee and created the NCI Fellows Outreach Committee.

Kristin Fabre Image

Organs-on-Chips to Screen for Drug Efficacy and Toxicity

Thursday, 9 July 2015 at 14:00

Add to Calendar ▼2015-07-09 14:00:002015-07-09 15:00:00Europe/LondonOrgans-on-Chips to Screen for Drug Efficacy and ToxicitySELECTBIOenquiries@selectbiosciences.com

The Tissue Chip Program is comprised of several academic and government entities, aimed to bioengineer microphysiological platforms (or chips) that mimic human organ systems.  These MPS platforms would be utilized for predicting efficacy and toxicity of candidate compounds faster, cheaper and with less use of animal models compared with current methods.  The over-arching goal at the end of the 5-year project is to incorporate human iPSC-dervied cell sources (inducible pluripotent stem cells) into the corresponding organ modules, and then to create an integrated Human-on-a-Chip as a way to study drug response observed within the human body.


Add to Calendar ▼2015-07-08 00:00:002015-07-09 00:00:00Europe/LondonOrgan-on-a-Chip ConferenceSELECTBIOenquiries@selectbiosciences.com